a(CHEBI:xanomeline) decreases path(MESH:Hallucinations)

View Subject View Object

PubMed:26813123

In a large-scale placebo-controlled clinical trial, it was demonstrated that xanomeline, a muscarinic agonist with reasonable selectivity for M1/M4 receptors, exhibits a positive effect in minimizing, in a dose-dependent manner, cognitive and psychiatric symptoms in AD, including memory deficit, mood disturbance, agitation and hallucinations

Related Edges 4

• a(CHEBI:xanomeline) increases bp(GO:cognition)
• a(CHEBI:xanomeline) increases bp(GO:memory)
• a(CHEBI:xanomeline) decreases path(MESH:"Mood Disorders")
• a(CHEBI:xanomeline) decreases path(MESH:"Psychomotor Agitation")

MeSH

Alzheimer Disease

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.

---